ASH 2020 | Dara plus IRd treatment for newly-diagnosed myeloma
Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses a study aiming to evaluate the efficacy and safety of a combined of daratumumab (dara) and IRd (ixazomib, lenalidomide, and dexamethasone) for the treatment of newly-diagnosed multiple myeloma (MM) patients. Dara-IRd is a treatment consisting of three oral agents and one, dara, administered parenterally. This line of treatment worked particularly well in the ongoing pandemic, as the patients only had to come to the clinic every four weeks, thus limiting their contact with other patients and reducing the risk of contracting COVID-19. The dara-IRd regimen was remarkably effective, with a 24-month overall survival (OS) in 97% of the patients and progression-free survival (PFS) of over 85%. These findings suggest that daratumumab has the potential to become a key induction therapy in newly-diagnosed MM patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
